Skip to main content
Figure 6 | Journal of Hematology & Oncology

Figure 6

From: Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition

Figure 6

Targeting the VEGF-independent cords. VEGF stimulated ADSC/ECFC co-cultures established for 4 days were treated with a concentration response of suramin (a) or combretastatin (b). The effects on the tube length of the established cords were continuously monitored from the day of drug addition. (c) Continuous monitoring of the effect of ramucirumab (Ram), a gamma secretase inhibitor (GSI; LY411575), or the Ram/GSI combination on the tube length of 4 day established cords. (d) Images of blood vessels stained with CD31 within the implants after treatment with IgG, ramucirumab (Ram), a gamma secretase inhibitor (GSI; LY411575), or the combination of Ram and the GSI beginning after 4 days of establishment (left). Graph of the percent area of CD31 after 4 days of treatment beginning on day 4 (right). n = 10 per treatment group. * = p < 0.01 vs. hIgG control. † = p < 0.001 vs. all other groups.

Back to article page